Skip to main content

Advertisement

SpringerLink
Log in

Should oral bisphosphonates be standard of care in women with early breast cancer?

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

There is increasing evidence that oral clodronate has important clinical benefits in early breast cancer. Longer-term follow-up data from two out of three randomized studies have shown that adjuvant clodronate improves survival. This article outlines the results of these studies and discusses the potential role for other bisphosphonates, such as ibandronate and zoledronic acid, in the adjuvant treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. RL Theriault GN Hortobagyi (1992) ArticleTitleBone metastasis in breast cancer Anticancer Drugs 3 455–462 Occurrence Handle1450438 Occurrence Handle1:STN:280:ByyD1c7ot10%3D

    PubMed  CAS  Google Scholar 

  2. RE Coleman (1997) ArticleTitleSkeletal complications of malignancy Cancer 80 IssueIDSuppl 8 1588–1594 Occurrence Handle9362426 Occurrence Handle1:STN:280:DyaK1c%2Fis1Onuw%3D%3D

    PubMed  CAS  Google Scholar 

  3. Pavlakis N, Stockler M (2002) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 1: CD003474

  4. JR Ross Y Saunders PM Edmonds S Patel KE Broadley SR Johnston (2003) ArticleTitleSystematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer BMJ 30 469

    Google Scholar 

  5. JR Gralow (2002) ArticleTitleBisphosphonates as adjuvant treatment for breast cancer BMJ 325 1051–1052 Occurrence Handle12424151

    PubMed  Google Scholar 

  6. Diel IJ, Solomayer EF: Bisphosphonates in the reduction of metastases in breast cancer – results of the extended follow-up of the first study population. Proc Am Soc Clin Oncol 19: (abs 314), 2000

  7. Jaschke A, Bastert G, Solomayer EF, Costa S, Schuetz F, Diel IJ: Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow – a longtime follow-up. Proc Am Soc Clin Oncol 23: (abs 529), 2004

  8. T Powles S Paterson J Kanis E McCloskey S Ashley A Tidy K Rosenqvist I Smith L Ottestad S Legault M Pajunen A Nevantaus E Mannisto A Suovuori S Atula J Nevalainen L Pylkkanen (2002) ArticleTitleRandomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 20 3219–3224 Occurrence Handle12149294

    PubMed  Google Scholar 

  9. Powles T, Paterson A, McCloskey E, Kurkilahti M, Kanis J: Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. Proc Am Soc Clin Oncol 23: (abs 528), 2004

  10. T Saarto C Blomqvist P Virkkunen I Elomaa (2001) ArticleTitleAdjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 19 10–17 Occurrence Handle11134190 Occurrence Handle1:STN:280:DC%2BD38%2Fls1SqsQ%3D%3D

    PubMed  CAS  Google Scholar 

  11. Saarto T, Vehmanen L, Blomqvist C, Elomaa I: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment. Proc Am Soc Clin Oncol 23: (abs 527), 2004

  12. Kokufu I, Kohno N, Takao S, Yamamoto M, Miyashita M, Kohno S, Kimura F: Adjuvant pamidronate therapy prevents. Proc Am Soc Clin Oncol 23: (abs 530), 2004

  13. AH Paterson TJ Powles JA Kanis E McCloskey J Hanson S Ashley (1993) ArticleTitleDouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J Clin Oncol 11 59–65 Occurrence Handle8418243 Occurrence Handle1:STN:280:ByyC3MrnvVY%3D

    PubMed  CAS  Google Scholar 

  14. AG Robertson NS Reed SH Ralston (1995) ArticleTitleEffect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study J Clin Oncol 13 2427–2430 Occurrence Handle7666103 Occurrence Handle1:STN:280:ByqA1MrltVU%3D

    PubMed  CAS  Google Scholar 

  15. G Pluijm Particlevan der H Vloedgraven E Beek Particlevan L Wee-Pals Particlevan der C Lowik S Papapoulos (1996) ArticleTitleBisphosphonates inhibit adhesion of breast cancer cells to bone matrices in vitro J Clin Invest 98 698–705 Occurrence Handle10.1172/JCI118841 Occurrence Handle8698861

    Article  PubMed  Google Scholar 

  16. S Magnetto S Boissier PD Delmas P Clezardin (1999) ArticleTitleAdditive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone Int J Cancer 83 263–269 Occurrence Handle10471537 Occurrence Handle1:STN:280:DyaK1MvgtVKrtg%3D%3D

    PubMed  CAS  Google Scholar 

  17. S Boissier M Ferreras O Peyruchaud S Magnetto FH Ebetino M Colombel P Delmas JM Delaisse P Clezardin (2000) ArticleTitleBisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 2949–2954 Occurrence Handle10850442 Occurrence Handle1:STN:280:DC%2BD3czgs1Kitw%3D%3D

    PubMed  CAS  Google Scholar 

  18. O Fromigue L Lagneaux J-J Body (2000) ArticleTitleBisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 15 2211–2221 Occurrence Handle11092402 Occurrence Handle1:STN:280:DC%2BD3MzgsFKmuw%3D%3D

    PubMed  CAS  Google Scholar 

  19. P Fournier S Boissier S Filleur J Guglielmi F Cabon M Colombel P Clezardin (2002) ArticleTitleBisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 6538–6544 Occurrence Handle12438248

    PubMed  Google Scholar 

  20. D Tripathy M Lichinitzer A Lazarev SA MacLachlan J Apffelstaedt M Budde B Bergstrom (2004) ArticleTitleMF 4434 Study Group: Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial Ann Oncol 15 743–750 Occurrence Handle15111341 Occurrence Handle1:STN:280:DC%2BD2c3htFymsw%3D%3D

    PubMed  CAS  Google Scholar 

  21. JJ Body IJ Diel M Lichinitzer A Lazarev M Pecherstorfer R Bell D Tripathy B Bergstrom (2004) ArticleTitleOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies Br J Cancer 90 1133–1137 Occurrence Handle15026791 Occurrence Handle1:STN:280:DC%2BD2c7jtlCiuw%3D%3D

    PubMed  CAS  Google Scholar 

  22. R Bell IJ Diel JJ Body B Bergström (2004) ArticleTitleRenal safety of ibandronate in patients with bone metastases from breast cancer: phase III trial results Eur J Cancer Suppl 2 132

    Google Scholar 

  23. M Borner W Scheithauer C Twelves J Maroun H Wilke (2001) ArticleTitleAnswering patients’ needs: oral alternatives to intravenous therapy Oncologist 6 IssueIDSuppl 4 12–16 Occurrence Handle11585969

    PubMed  Google Scholar 

  24. M Gnant H Hausmaninger H Samonigg B Mlineritsch S Taucher G Luschin-Ebengreuth R Jakesz (2002) ArticleTitleChanges in bone mineral density caused by anastrazole or tamoxifen in combination with goserelin (+/− zoledronate) as adjuvant treatment for hormone receptor positive premenopausal breast cancer: results of a randomised multicenter trial Breast Cancer Res Treat 76 IssueIDSuppl 1 S31

    Google Scholar 

  25. R Theriault R Jakesz M Gnant J Gralow (2004) ArticleTitleThe evolving role of bisphosphonates for the prevention of cancer treatment-induced bone loss in patients with breast cancer Bone 34 IssueIDSuppl 1 S90

    Google Scholar 

  26. R Coleman J Gralow R Bell A Lipton (2004) ArticleTitleZoledronic acid is being investigated for the prevention of bone metastases in patients with early stage breast cancer Bone 34 IssueIDSuppl 1 S85

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada, M4N 3M5

    Mark Clemons & Sunil Verma

Authors
  1. Mark Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunil Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Clemons.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clemons, M., Verma, S. Should oral bisphosphonates be standard of care in women with early breast cancer?. Breast Cancer Res Treat 90, 315–318 (2005). https://doi.org/10.1007/s10549-004-4259-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-004-4259-3

Keywords

Search

Navigation